Efficacy and safety of apalutamide, abiraterone acetate, and bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer
Compared to Bicalutamide, the novel endocrine therapies Apalutamide and Abiraterone both significantly prolong PFS, PSA-PFS, and improve PSA response rates.
Authors
- Tao Wu (ORCID: https://orcid.org/0000-0002-0629-8421)
- Huiyu Gao
- Hao Peng (ORCID: https://orcid.org/0000-0001-6277-662X)
- Jiabin Zhang (ORCID: https://orcid.org/0000-0001-6400-077X)
- Junjie Zhou (ORCID: https://orcid.org/0000-0002-1323-053X)
- Qiang Wang (ORCID: https://orcid.org/0000-0003-4392-0889)
Institutions
- North Sichuan Medical University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
- Yueyang Hospital (CN)
- Dazhou Central Hospital (CN)
- Anyang Hospital of Traditional Chinese Medicine (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.3389/fonc.2025.1656216
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Sichuan Province